UsAgainstAlzheimer's Endorses the CHANGE Act


Innovative, bipartisan bicameral legislation has a multi-pronged approach to tackling Alzheimer's for patients and caregivers 

Washington, DC (February 7, 2018) - UsAgainstAlzheimer's today announced its strong support for the Concentrating on High-Value Alzheimer's Needs to Get to an End (CHANGE) Act. The bill, introduced today by Senators Shelley Moore Capito (R-WV), Roger Wicker (R-MS), Debbie Stabenow (D-MI), and Bob Menendez (D-NJ) and Representatives Peter Roskam (R-IL) and Linda Sanchez (D-CA), is a highly-targeted approach to overcome barriers to a faster cure for Alzheimer's disease, the third leading cause of death of Americans according to researchers. The CHANGE Act encourages timely and accurate assessment, detection and diagnosis, supports innovative approaches to support family caregivers, and removes regulatory barriers to disease modifying treatments. The legislation was developed in close partnership between its sponsors and UsAgainstAlzheimer's (UsA2). 

"Alzheimer's is a burdensome and relentless disease for American families. The path to relieving that burden requires a highly-targeted approach to improve diagnosis rates, clinical research participation, and physician care practices. The CHANGE Act addresses this multi-faceted dynamic by tackling Alzheimer's on all fronts, an approach which is essential to moving us closer to getting innovative treatments to more families affected by the disease," said George Vradenburg, co-founder and Chairman of UsAgainstAlzheimer's. "UsAgainstAlzheimer's is grateful to Senators Capito, Wicker, Stabenow and Menendez and Representatives Roskam and Sanchez for their steadfast leadership on this issue. We're honored to have played a key role in the CHANGE Act and urge all members to sign on as cosponsors.

"Increased funding for Alzheimer's research through the federal budget and appropriations continues to be crucial and we will continue to push for Congress to make investments in a cure commensurate with the burden of the disease on American families and our economy. At the same time, it is equally important that we facilitate timely assessment and diagnosis, provide relief for caregivers, and accelerate progress for disease modifying treatments. The CHANGE Act provides an innovative and highly-targeted approach to multiple barriers to faster cures and better care."

A summary of the CHANGE Act can be found here.

"The CHANGE Act takes a multi-prong approach to help the millions of Americans who are battling or are affected by this devastating disease. Having lost both of my parents to Alzheimer's, I truly understand the emotional, physical, and financial toll it takes on patients and their caregivers. This legislation will encourage early assessment and diagnosis to help lessen that burden and bring us one step closer to a cure," Senator Capito said.

"The cruelty of Alzheimer's holds no prejudice. Irrespective of race or gender, this neurodegenerative disease is projected to affect 240,000 Illinoisans over age 65 by 2025," said Representative Roskam. "This legislation will aid in earlier identification and treatment of this disease and provide caregivers appropriate training to care for loved ones experiencing cognitive decline."

Follow updates on the CHANGE Act on Twitter at #CHANGEAlzNow.

UsA2 works to overcome barriers to faster cures and better care by mobilizing American families to demand a cure, elevating investment in research, increasing the speed, efficiency and diversity of Alzheimer's clinical trials; boosting attention to brain health and early detection; including the insights and preferences of patients and caregivers in drug development; and advancing national Alzheimer's care goals and policies. The organization engages those most affected by the disease - and best positioned to fight it - through its eight networks



Media Contact:

Ranit Schmelzer